CoChat

Vortioxetine for depression in adults

Open access
Koesters, Markus, Ostuzzi, Giovanni, Guaiana, Giuseppe, Breilmann, Johanna, Barbui, Corrado · 2017 · Cochrane Database of Systematic Reviews
Cited by 56

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Major depressive disorder is a common mental disorder affecting a person's mind, behaviour and body. It is expressed as a variety of symptoms and is associated with substantial impairment. Despite a range of pharmacological and non-pharmacological treatment options, there is still room for improvement of the pharmacological treatment of depression in terms of efficacy and tolerability. The latest available antidepressant is vortioxetine. It is assumed that vortioxetine's antidepressant action is related to a direct modulation of serotonergic receptor activity and inhibition of the serotonin transporter. The mechanism of action is not fully understood, but it is claimed to be novel. Vortioxetine was placed in the category of "Other" antidepressants and may therefore provide an alternative to existing antidepressant drugs. OBJECTIVES: To assess the efficacy and acceptability of vortioxetine compared with placebo and other antidepressant drugs in the treatment of acute depression in adults. SEARCH METHODS: We searched Cochrane's Depression, Anxiety and Neurosis Review Group's Specialised Register to May 2016 without applying any restrictions to date, language or publication status. We checked reference lists of relevant studies and reviews, regulatory agency reports and trial databases. SELECTION CRITERIA: We included randomised controlled trials comparing the efficacy, tolerability, or both of vortioxetine versus placebo or any other antidepressant agent in the treatment of acute depression in adults. DATA COLLECTION AND ANALYSIS: Two review authors independently selected the studies and extracted data. We extracted data on study characteristics, participant characteristics, intervention details and outcome measures in terms of efficacy, acceptability and tolerability. We analysed intention-to-treat (ITT) data only and used risk ratios (RR) as effect sizes for dichotomous data and mean differences (MD) for continuous data with 95% confidence intervals (CI). Meta-analyses used random-effects models. MAIN RESULTS: We included 15 studies (7746 participants) in this review. Seven studies were placebo controlled; eight studies compared vortioxetine to serotonin-norepinephrine reuptake inhibitors (SNRIs). We were unable to identify any study that compared vortioxetine to antidepressant drugs from other classes, such as selective serotonin reuptake inhibitors (SSRIs).Vortioxetine may be more effective than placebo across the three efficacy outcomes: response (Mantel-Haenszel RR 1.35, 95% CI 1.22 to 1.49; 14 studies, 6220 participants), remission (RR 1.32, 95% CI 1.15 to 1.53; 14 studies, 6220 participants) and depressive symptoms measured using the Montgomery-Åsberg Depression Scale (MADRS) (score range: 0 to 34; higher score means worse outcome: MD -2.94, 95% CI -4.07 to -1.80; 14 studies, 5566 participants). The quality of the evidence was low for response and remission and very low for depressive symptoms. We found no evidence of a difference in total dropout rates (RR 1.05, 95% CI 0.93 to 1.19; 14 studies, 6220 participants). More participants discontinued vortioxetine than placebo because of adverse effects (RR 1.41, 95% CI 1.09 to 1.81; 14 studies, 6220 participants) but fewer discontinued due to inefficacy (RR 0.56, 95% CI 0.34 to 0.90, P = 0.02; 14 studies, 6220 participants). The quality of the evidence for dropouts was moderate.The subgroup and sensitivity analyses did not reveal factors that significantly influenced the results.In comparison with other antidepressants, very low-quality evidence from eight studies showed no clinically significant difference between vortioxetine and SNRIs as a class for response (RR 0.91, 95% CI 0.82 to 1.00; 3159 participants) or remission (RR 0.89, 95% CI 0.77 to 1.03; 3155 participants). There was a small difference favouring SNRIs for depressive symptom scores on the MADRS (MD 1.52, 95% CI 0.50 to 2.53; 8 studies, 2807 participants). Very low quality evidence from eight studies (3159 participants) showed no significant differences between vortioxetine and the SNRIs as a class for total dropout rates (RR 0.89, 95% CI 0.73 to 1.08), dropouts due to adverse events (RR 0.74, 95% CI 0.51 to 1.08) and dropouts due to inefficacy (RR 1.52, 95% CI 0.70 to 3.30).Against individual antidepressants, analyses suggested that vortioxetine may be less effective than duloxetine in terms of response rates (RR 0.86, 95% CI 0.79 to 0.94; 6 studies, 2392 participants) and depressive symptoms scores on the MADRS scale (MD 1.99, 95% CI 1.15 to 2.83; 6 studies; 2106 participants). Against venlafaxine, meta-analysis of two studies found no statistically significant differences (response: RR 1.03, 95% CI 0.85 to 1.25; 767 participants; depressive symptom scores: MD 0.02, 95% CI -2.49 to 2.54; 701 participants). In terms of number of participants reporting at least one adverse effect (tolerability), vortioxetine was better than the SNRIs as a class (RR 0.90, 95% CI 0.86 to 0.94; 8 stu

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd011520.pub2

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Research works printed but not linked: 55

  1. Baldwin, 2011, A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in MDD treatment, European Neuropsychopharmacology, 21, S390, 10.1016/S0924-977X(11)70627-7 · doi:10.1016/s0924-977x(11)70627-7
  2. Baldwin, 2012, A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD), European Neuropsychopharmacology, 22, 482, 10.1016/j.euroneuro.2011.11.008 · DOI
  3. Henigsberg, 2011, Efficacy and tolerability of multiple doses of LU AA21004 in an 8-week trial of adults with major depressive disorder, European Neuropsychopharmacology, 21, S393, 10.1016/S0924-977X(11)70632-0 · DOI
  4. Jacobsen, 2015, A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder, Journal of Clinical Psychiatry, 76, 575, 10.4088/JCP.14m09335 · DOI · Paper page
  5. Katona, 2012, A randomised, double-blind, placebo controlled, active-referenced study of the multimodal antidepressant Lu AA21004 in the treatment of elderly depressed patients, European Neuropsychopharmacology, 22, S258, 10.1016/S0924-977X(12)70388-7 · DOI
  6. Mahableshwarkar, 2013, A randomized, double-blind trial of 2.5mg and 5mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder, Current Medical Research and Opinion, 29, 217, 10.1185/03007995.2012.761600 · DOI · Paper page
  7. Jacobson W Olsen C Mahableshwarkar A Yinzhong C Keefe R Effect of vortioxetine on functional capacity in patients with major depressive disorder with self-reported cognitive dysfunction 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 29 Aug - 1 Sept; Amsterdam Netherlands 2015 S460 · doi:10.1016/s0924-977x(15)30622-2
  8. Keefe, 2014, Efficacy of vortioxetine on cognitive function in patients with major depressive disorder: cognitive test performance results: from a randomized, double-blind, duloxetine-referenced, placebo-controlled, Neuropsychopharmacology, 39, S389
  9. Harrison J Assessment of cognitive dysfunction in patients with depression - which test is best? 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 29 Aug - 1 Sept; Amsterdam Netherlands 2015 S669 · doi:10.1016/s0924-977x(15)30957-3
  10. Wang, 2015, Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study, Current Medical Research and Opinion, 31, 785, 10.1185/03007995.2015.1014028 · DOI · Paper page
  11. Browning M Smith J Conen S Smallman R Buchbjerg J Larsen Kg Vortioxetine reduces BOLD signal during performance of the N-back task in subjects remitted from depression and healthy control participants 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 Aug 29 to Sep 1; Amsterdam, Netherlands 2015 S314 5 · DOI
  12. Conen S McKie S Smallman RP Dutta A Dawson Gr Smith J Effects of vortioxetine on resting-state activity in subjects remitted from depression and healthy controls 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 Aug 29 to Sep 1; Amsterdam, Netherlands 2015 S442 · doi:10.1016/s0924-977x(15)30593-9
  13. Jacobsen, 2015, Effect of vortioxetine vs. escitalopram on sexual functioning in adults with well-treated major depressive disorder experiencing SSRI-induced sexual dysfunction, Journal of Sexual Medicine, 12, 2036, 10.1111/jsm.12980 · DOI · Paper page
  14. Jacobsen, 2015, Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study, International Clinical Psychopharmacology, 30, 255, 10.1097/YIC.0000000000000081 · DOI · Paper page
  15. Haggstrom L Nielsen RZ Danchenko N Poulsen L A randomised, double-blind, study of vortioxetine versus agomelatine in adults with major depressive disorder (MDD) with inadequate response to SSRI/SNRI treatment 26th European College of Neuropsychopharmacology, ECNP Congress; 2013 Oct 5-9; Barcelona, Spain 2013 S412 · DOI
  16. Haggstrom, 2013, Randomized, double-blind, study of vortioxetine versus agomelatine in adults with MDD after inadequate response to SSRI or SNRI treatment, European Psychiatry, 28, 3009
  17. Papakostas, 2014, Efficacy and tolerability of vortioxetine is independent of previous treatment in MDD patients switched after an inadequate response, European Neuropsychopharmacology, 24, S466, 10.1016/S0924-977X(14)70745-X · doi:10.1016/s0924-977x(14)70745-x
  18. American Psychiatric Association, 1980, Diagnostic and Statistical Manual of Mental Disorders (DSM-III)
  19. American Psychiatric Association, 1987, Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R)
  20. American Psychiatric Association, 1994, .
  21. American Psychiatric Association, 2000, Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR)
  22. American Psychiatric Association, 2013, Diagnostic and Statistical Manual of Mental Disorders: DSM-5, 10.1176/appi.books.9780890425596 · DOI · Paper page
  23. Baldwin, 2016, The safety and tolerability of vortioxetine: analysis of data from randomized placebo-controlled trials and open-label extension studies, Journal of Psychopharmacology (Oxford, England), 30, 242, 10.1177/0269881116628440 · DOI · Paper page
  24. Barbui, 2004, "Wish bias" in antidepressant drug trials?, Journal of Clinical Psychopharmacology, 24, 126, 10.1097/01.jcp.0000115665.45074.0d · DOI · Paper page
  25. Bauer, 2008, Prescribing patterns of antidepressants in Europe: results from the Factors Influencing Depression Endpoints Research (FINDER) study, European Psychiatry, 23, 66, 10.1016/j.eurpsy.2007.11.001 · DOI · Paper page
  26. Berhan, 2014, Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials, BMC Psychiatry, 14, 276, 10.1186/s12888-014-0276-x · DOI · Paper page
  27. Bull, 2002, Discontinuing or switching selective serotonin-reuptake inhibitors, Annals of Pharmacotherapy, 36, 578, 10.1345/aph.1A254 · doi:10.1345/aph.1a254 · Paper page
  28. Citrome, 2014, Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?, International Journal of Clinical Practice, 68, 60, 10.1111/ijcp.12350 · DOI · Paper page
  29. Citrome, 2016, Vortioxetine for major depressive disorder: an indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed, Journal of Affective Disorders, 196, 225, 10.1016/j.jad.2016.02.042 · DOI
  30. Du Jardin, 2016, Differential interaction with the serotonin system by S-ketamine, vortioxetine, and fluoxetine in a genetic rat model of depression, Psychopharmacology, 233, 2813, 10.1007/s00213-016-4327-5 · DOI
  31. Feighner, 1972, Diagnostic criteria for use in psychiatric research, Archives of General Psychiatry, 26, 57, 10.1001/archpsyc.1972.01750190059011 · DOI · Paper page
  32. Florea I Loft H Danchenko N Rive B Brignone M Merikle E Vortioxetine effects on overall patient functioning in patients with major depressive disorder 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 Aug 29 to Sep 1; Amsterdam, Netherlands 2015 S436 · doi:10.1016/s0924-977x(15)30584-8
  33. Fu, 2015, The efficacy and safety of 5 mg/d Vortioxetine compared to placebo for major depressive disorder: a meta-analysis, Psychopharmacology, 232, 7, 10.1007/s00213-014-3633-z · DOI
  34. Gartlehner, 2012, How should primary care doctors select which antidepressants to administer?, Current Psychiatry Reports, 14, 360, 10.1007/s11920-012-0283-x · DOI
  35. Guaiana, 2013, Agomelatine versus other antidepressive agents for major depression, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD008851.pub2 · DOI · Paper page
  36. Guy, 1970, Manual for the ECDEU Assessment Battery 2
  37. Hamilton, 1960, A rating scale for depression, Journal of Neurology, Neurosurgery and Psychiatry, 23, 56, 10.1136/jnnp.23.1.56 · DOI · Paper page
  38. Koesters, 2013, Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials, British Journal of Psychiatry, 203, 179, 10.1192/bjp.bp.112.120196 · DOI · Paper page
  39. Li, 2016, The efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta-analysis of randomized controlled trials, Neuropsychiatric Disease and Treatment, 12, 523
  40. Meeker, 2015, The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis, Systematic Reviews, 4, 21, 10.1186/s13643-015-0001-y · DOI · Paper page
  41. Montgomery, 1979, A new depression scale designed to be sensitive to change, British Journal of Psychiatry, 134, 382, 10.1192/bjp.134.4.382 · DOI · Paper page
  42. National Institute for Health and Care Excellence, 2009, Depression in Adults. CG90
  43. Pehrson, 2016, Regional distribution of serotonergic receptors: a systems neuroscience perspective on the downstream effects of the multimodal-acting antidepressant vortioxetine on excitatory and inhibitory neurotransmission, CNS Spectrums, 21, 162, 10.1017/S1092852915000486 · DOI · Paper page
  44. Pigott, 2011, STAR*D: a tale and trail of bias, Ethical Human Psychology and Psychiatry, 13, 6, 10.1891/1559-4343.13.1.6 · DOI · Paper page
  45. The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014
  46. Saito, 2010, Evaluation of the DSM-IV and ICD-10 criteria for depressive disorders in a community population in Japan using item response theory, International Journal of Methods in Psychiatric Research, 19, 211, 10.1002/mpr.320 · DOI · Paper page
  47. Schueler, 2011, A systematic review of duloxetine and venlafaxine in major depression, including unpublished data, Acta Psychiatrica Scandinavica, 123, 247, 10.1111/j.1600-0447.2010.01599.x · DOI · Paper page
  48. Spitzer, 1978, Research diagnostic criteria: rationale and reliability, Archives of General Psychiatry, 35, 773, 10.1001/archpsyc.1978.01770300115013 · DOI · Paper page
  49. Stahl, 2015, Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): blocking 5HT3 receptors enhances release of serotonin, norepinephrine, and acetylcholine, CNS Spectrums, 20, 455, 10.1017/S1092852915000346 · DOI
  50. Thase, 2016, A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults, European Neuropsychopharmacology, 26, 979, 10.1016/j.euroneuro.2016.03.007 · DOI · Paper page
  51. Weinmann, 2008, Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis, Psychopharmacology, 196, 511, 10.1007/s00213-007-0975-9 · DOI
  52. World Health Organization (WHO), 1992, The ICD-10 Classification of Mental and Behavioural Disorders
  53. Zhang, 2013, Preliminary study of patterns of medication use for depression treatment in China, Asia-Pacific Psychiatry: Official Journal of the Pacific Rim College of Psychiatrists, 5, 231, 10.1111/appy.12022 · DOI
  54. Zhang, 2015, The US Food and Drug Administration's perspective on the new antidepressant vortioxetine, Journal of Clinical Psychiatry, 76, 8, 10.4088/JCP.14r09164 · DOI
  55. Zorzela, 2014, Quality of reporting in systematic reviews of adverse events: systematic review, BMJ (Clinical Research Ed.), 348, f7668

Cited by

See all 56

Metadata

Authors
Koesters, M., Ostuzzi, G., Guaiana, G., Breilmann, J., & Barbui, C.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2017-07-05
Volume
2017
Issue
7
Pages
CD011520-CD011520
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W1497985356
Cited by
56
References
27
FWCI
2.78
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Vortioxetine for depression in adults. https://app.cochat.ai/papers/10.1002/14651858.cd011520.pub2
The paper
Koesters, M., Ostuzzi, G., Guaiana, G., Breilmann, J., & Barbui, C. (2017). Vortioxetine for depression in adults. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd011520.pub2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.